within Pharmacolibrary.Drugs.ATC.R;

model R06AX58
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 6.944444444444445e-06,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,
    adminCount     = 1,
    Vd             = 0.04,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );
  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>PyrrobutamineCombinations</td></tr><tr><td>ATC code:</td><td>R06AX58</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>40</td><td>L</td></tr>
    <tr><td>clearance:</td><td>25</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pyrrobutamine is an antihistamine of the ethylene diamine class, historically used for the symptomatic relief of allergies, such as hay fever and urticaria. It is not widely used today due to the availability of newer agents with improved safety profiles and is not approved in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated for a hypothetical standard healthy adult population, as no referenced publication exists for pyrrobutamine combinations.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end R06AX58;
